drugset / Trial / NCT02532998

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

NCT02532998

Phase 1 Completed 40 enrolled AstraZeneca
RandomizedCrossoverSingle-blindBasic science

Summary

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eplerenone Unknown 100 mg
Subject balcinrenone Small molecule Oral
Background Fludrocortisone Other / unclassified 0.1 mg

Indications

No indication recorded.